Navigation Links
PneumRx, Inc. Receives FDA Approval to Commence Pivotal Clinical Trial of RePneu Lung Volume Reduction Coil (RePneu LVRC) System
Date:5/15/2012

MOUNTAIN VIEW, Calif., May 15, 2012 /PRNewswire/ -- PneumRx, Inc. (www.pneumrx.com), a medical device company dedicated to bringing innovation and improvements to the treatment of lung disease, today announced that it has received FDA approval to commence a 30-site pivotal clinical trial to support a PMA application for the RePneu LVRC System.

(Logo:  http://photos.prnewswire.com/prnh/20120514/SF06703LOGO)

The RePneu LVRC System is a minimally invasive device intended to improve lung function in emphysema patients by bronchoscopically implanting Nitinol coils into the lungs to compress diseased tissue (lung volume reduction), restore elastic recoil, and adjust lung compliance.  This treatment offers a minimally invasive alternative to lung volume reduction surgery to a broad range of emphysema patients. 

The RePneu LVRC has already undergone extensive clinical studies in Europe, with impressive results in over 250 treatments.  The majority of subjects who underwent RePneu LVRC treatment in PneumRx's European clinical trials experienced significant improvement in lung function, exercise capacity and quality of life at both 6 months and one year after treatment, with minimal risk.  74% of all clinical subjects maintained a clinically significant improvement in exercise capacity at 12 months post-treatment and 96% experienced significant improvement in quality of life.

Specifically, RePneu LVRC subjects experienced a mean improvement in Six-Minute Walk Test of 62 meters; a 12% increase in FEV1, a 10% decrease in Residual Volume  and a decrease of 12 points in the St. George's Respiratory Questionnaire, at 12 months.  The European clinical trial results were used to support PneumRx's CE Mark, and the RePneu LVRC System has been commercially available in Europe since 2010.

The RePneu LVRC has proven effective in patients with both heterogeneous and homogeneous disease, in both the upper and lower lobes, and it works independently of collateral ventilation.  The safety profile of the RePneu LVRC System is comparable to that of a simple bronchoscopy procedure, with the majority of adverse results occurring, and resolving, within 30 days of treatment.  Patients generally return home from the hospital the day after the treatment.

"We are thrilled to have IDE approval for the RePneu LVRC and are eager to bring this exciting technology to the United States," said Erin McGurk, PneumRx's President and CEO.  "It has been so gratifying to see the benefits the RePneu LVRC treatment has brought to emphysema patients in Europe and we are especially pleased to be able to bring these benefits to a greater number of patients suffering from this debilitating disease here in the United States.  We plan to treat over 300 subjects in our pivotal trial, and expect to start enrolling clinical subjects in the coming months.  We look forward to submitting the pivotal trial results in support of a PMA application to sell the RePneu LVRC System in the United States."

"The entire PneumRx team, in partnership with our accomplished team of Physician Advisors, has worked tirelessly to support the RePneu LVRC IDE application and design an appropriate clinical trial," stated Kara Andersen Reiter, Vice President of Regulatory Affairs at PneumRx.  "We are grateful to the FDA team who reviewed our IDE application and worked with us to bring our submission over the finish line."

About PneumRx, Inc.

PneumRx, Inc. is a rapidly growing medical device company focused on the development and commercialization of innovative products to treat emphysema using minimally-invasive techniques.  It is a privately held company located in Mountain View, California.

Website

www.pneumrx.com


'/>"/>
SOURCE PneumRx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PneumRx, Inc. Raises $33 Million in Capital
2. PneumRx, Inc. Announces CE Mark Approval for Its RePneu® Lung Volume Reduction Coil (LVRC™) System
3. MAQUET Cardiovascular Receives FDA 510(k) Clearance For New Mega® Intra-Aortic Balloon Catheter Sizes
4. Flexpoint Receives Purchase Order for Medical Device Used in Procedure Performed Millions of Times Annually
5. Stiefel receives US FDA approval of Fabior™ Foam, 0.1%
6. New Chronic Wound Treatment Device Receives Award from Veterans Healthcare Program
7. Marshall Edwards Receives $4 Million Subscription From Novogen In Rights Offering
8. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
9. Alexza Receives Complete Response Letter for Adasuve™ NDA
10. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
11. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2019)... ... ... Data integration has been a pharma industry buzzword for the last few ... staff are still working in silos and are not aware of all the data ... more, and nearly one-third of qualified investigators may be overlooked. Innovations in data mapping ...
(Date:12/2/2019)... ... December 02, 2019 , ... Strong public health departments engaged ... and play. Striving to fulfill their crucial mission, more and more health departments ... the Public Health Accreditation Board (PHAB). Today, PHAB announced it has awarded initial ...
(Date:11/30/2019)... (PRWEB) , ... November 29, 2019 , ... ... breast cancer screening, that uses deep learning algorithms to automatically detect potential breast ... Annual Radiological Society of North America (RSNA) meeting, December 1-6, 2019 (ScreenPoint Medical, ...
Breaking Medicine Technology:
(Date:12/6/2019)... ... 06, 2019 , ... Lasair Aesthetic Health Sponsors Toys for Tots to Give Free Toys to ... Who Bring in Toys During the Holidays , Lasair Aesthetic Health is spreading holiday cheer ... who bring in a toy or toys worth more than 25-dollars, will get FIVE units ...
(Date:12/6/2019)... , ... December 06, 2019 , ... Dr. Scott Howell, ... program, recently published research on the health benefits of coconut oil in the 7 ... and Its Effects on the Cardiometabolic Profile: A Structured Literature Review,” led by Dr. ...
(Date:12/5/2019)... ... December 05, 2019 , ... ... announced the Top 54 RHIT Degree Programs for 2020. The comprehensive research guide ... nation. Each program is evaluated based on curriculum quality, graduation rate, reputation, and ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... ... Tex-OE, Opuntia Mesocarp Extract®, provides protection from disruptions to cells and tissue and ... the menace of Jet Lag, is available in a dietary supplement product called ...
(Date:12/4/2019)... (PRWEB) , ... December 04, 2019 , ... UNC Health ... easily find their way around the campuses of UNC Medical Center in Chapel Hill ... two hospitals, parking garages, clinics and more. , The free interactive app, developed by ...
Breaking Medicine News(10 mins):